Our previous study confirmed that myeloid differentiation factor 2 (MD2) is the crosstalk mediator of various PCDs and that inhibition of MD2 effectively reduced stroke injury (Fang et al., 2021). The gene discussed is LY96; the disease is stroke disorder.